Less Ads, More Data, More Tools Register for FREE

Pin to quick picksXaar Regulatory News (XAR)

Share Price Information for Xaar (XAR)

Share Price is delayed by 15 minutes
Get Live Data
145.00    3.00 (2.11%)
Bid:
140.50
Ask:
144.50
Spread: 4.00 (2.847%)
Market Cap: £113.79m
XAR Live PriceLast checked at - London Stock Exchange

Intraday Xaar Share Chart

Interim Management Statement

2 Oct 2014 07:00

RNS Number : 2305T
Xaar PLC
02 October 2014
 



2 October 2014

 

Xaar plc

 

Interim Management Statement

Xaar plc ("Xaar", "the Group" or "the Company"), the digital inkjet printing technology Group headquartered in Cambridge, UK, is providing an Interim Management Statement covering trading from 1 July 2014.

 

As stated in the Interim Results announcement on 28 August 2014, demand for Xaar's products from the ceramic tile market softened during the third quarter of the year as a result of a slowdown in construction activity in China. The Company's exposure to China is significant, as almost half of the world's ceramic tile output is reported as manufactured and consumed in China. Revenue into the global ceramic tile market represented around two thirds of the Group's sales in 2013.

Monitoring of the ceramic tile market in China has indicated a further decline in activity resulting in excess manufacturing capacity being idled. As a consequence, forecast orders from Xaar's OEMs in this market for the remainder of the year have further reduced, such that the Board now expects total revenue for 2014 to be 5%-10% below the bottom of the previously announced range of £115-125 million.

Although visibility into 2015 remains low, based on all of the information currently available to the Group concerning the ceramic tile market in China, the Group is now planning to take action to reduce costs in anticipation of total Group revenue for 2015 being below £100 million.

Action will be taken immediately to reduce costs in line with the reduced expectation for sales in 2015. This is expected to result in a 15% reduction in operating expenditures, and potentially a total reduction in headcount (subject to consultation) of approximately 20% of the current global workforce of around 800 employees.

The cost reductions aim to achieve a reasonable level of financial operating performance in 2015, whilst ensuring that Xaar can fulfil its key strategic objectives.

Ian Dinwoodie, Chief Executive, commented, "We are highly disappointed to have to make this level of cost reduction given the progress achieved over the last four years. Our exposure to the ceramic tile market in China, which delivered such strong growth over the last few years, is now driving a reduction in our sales. This change re-emphasises the need for Xaar's revenues over time to become more broadly spread across multiple markets and applications. Our competitive position remains strong through our established market leading products, recently announced offerings, and planned future launches. Development efforts on both our Bulk technology and our Thin Film technology provide an excellent basis for our future success as the digitalisation of industrial and commercial printing continues".

A conference call for analysts will take place at 8.00am this morning. The conference call can be accessed by dialling +44 (0)203 139 4830 and using pin code 80375705#.

 

Contacts 

Xaar plc

Ian Dinwoodie, Chief Executive Officer

01223-423663

Alex Bevis, Finance Director

www.xaar.com

Tulchan Communications

Tom Buchanan

Christian Cowley

Victoria Huxster

 

020-7353-4200

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSBRBDGXSGBGSB
Date   Source Headline
26th Apr 20215:51 pmRNSHolding(s) in Company
22nd Apr 202112:18 pmRNSDirector Declaration
15th Apr 20212:24 pmRNSNotice of 2020 Preliminary Results
6th Apr 202112:12 pmRNSHolding(s) in Company
1st Apr 20211:50 pmRNSTotal Voting Rights
1st Mar 20215:18 pmRNSTotal Voting Rights
10th Feb 20212:25 pmRNSHolding(s) in Company
1st Feb 202111:01 amRNSTotal Voting Rights
28th Jan 20212:49 pmRNSHolding(s) in Company
21st Jan 202110:27 amRNSHolding(s) in Company
14th Jan 20217:00 amRNSTrading Statement
4th Jan 202111:38 amRNSTotal Voting Rights
1st Dec 20204:43 pmRNSTotal Voting Rights
9th Nov 202010:42 amRNSHolding(s) in Company
4th Nov 202011:00 amRNSUpdate on cyber security incident
3rd Nov 202011:29 amRNSGrant of options under SAYE Scheme
3rd Nov 202011:15 amRNSHolding(s) in Company
2nd Nov 202011:40 amRNSTotal Voting Rights
7th Oct 20207:00 amRNSNotice of cyber security incident
6th Oct 20204:48 pmRNSHolding(s) in Company
1st Oct 202012:59 pmRNSTotal Voting Rights
30th Sep 20207:00 amRNS2020 Interim Results
3rd Sep 20204:24 pmRNSHolding(s) in Company
3rd Sep 20201:20 pmRNSNotice of Interim Results
1st Sep 202010:42 amRNSTotal Voting Rights
5th Aug 202012:47 pmRNSTotal Voting Rights
3rd Aug 20208:59 amRNSChange of Adviser
16th Jul 20207:00 amRNSTrading Statement
9th Jul 20204:36 pmRNSPrice Monitoring Extension
1st Jul 20203:17 pmRNSConfirmation of Board Change & Succession
1st Jul 202011:47 amRNSTotal Voting Rights
5th Jun 20207:00 amRNSGrant of Options
2nd Jun 202011:16 amRNSTotal Voting Rights
2nd Jun 202011:13 amRNSResult of AGM
2nd Jun 20207:00 amRNSTrading Statement
15th May 202010:59 amRNSHolding(s) in Company
7th May 20207:00 amRNSNotice of Annual General Meeting
1st May 20203:10 pmRNSTotal Voting Rights
30th Apr 20202:27 pmRNSHolding(s) in Company
29th Apr 202012:04 pmRNSDisclosure of Rights attached to Equity Shares
29th Apr 202011:41 amRNSGrant of option
28th Apr 20205:27 pmRNSHolding(s) in Company
27th Apr 20202:23 pmRNSHolding(s) in Company
27th Apr 20202:00 pmRNSDirectorate Change - Appointment
24th Apr 20203:10 pmRNSHolding(s) in Company
24th Apr 20203:02 pmRNSAnnual Financial Report
23rd Apr 20202:35 pmRNSDirector/PDMR Shareholding
23rd Apr 20207:00 amRNSAnnual Financial Report
9th Apr 20209:15 amRNSHolding(s) in Company
6th Apr 20203:35 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.